<DOC>
	<DOCNO>NCT01431638</DOCNO>
	<brief_summary>This 36 week open-label extension canakinumab pre-filled syringe study safety tolerability patient frequent flare acute gouty arthritis .</brief_summary>
	<brief_title>Long-Term Safety Tolerability Canakinumab Prefilled Syringes Frequently Flaring Acute Gouty Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Gouty</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Compliance completion canakinumab PFS core study Unchanged significant clinical medical history entry core study Exclusion criterion : Physician judgment unsuitability study Pregnant nursing woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gout</keyword>
	<keyword>arthritis</keyword>
	<keyword>gout flare</keyword>
	<keyword>acute gout</keyword>
	<keyword>gouty</keyword>
	<keyword>rheumatic disease</keyword>
	<keyword>uric acid</keyword>
	<keyword>podagra</keyword>
</DOC>